References

Landmark project in China

Excellence in engineering References Landmark project in China

Reference

Landmark project in China


Founded in 1985, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (Shuyang) produces and sells a wide range of products, including high-quality plasma-derived medicinal products ("PDMP"). It has a production facility in Chengdu, China. The company also has its own R&D team, which is intensively developing both existing products and new ones. Plasma for fractionation is collected and tested in Shuyang's plasmapheresis centers and then transported to cold storage. However, Chinese regulations prohibit recovered plasma being used for fractionation. The collection of source plasma is growing rapidly because an expansion of the fractionation capacity in China is urgently needed. In 2016, Shuyang was one of the dominant manufacturers of Human Albumin and Immunoglobulin, with over 70% PDMP market share in China.

To meet the growing demand for PDMPs, Shuyang started a project to build a world-class, state-of-the-art large-scale multiproduct human plasma fractionation plant. Because Chinese companies have, until now, only fractionated 11 different plasma proteins, all major plasma companies are accelerating their R&D efforts to develop more products. For this purpose, they needed to find a global partner to draw up the concept and basic design of the new plant.

The concept design is the most influential phase of the entire project, as the most suitable process concept must be defined out of several different alternatives. This phase has the biggest impact on the investment cost and overall functionality of the plant. Ultimately, Shuyang was convinced that Neste Jacobs had the specific plasma fractionation expertise and requisite capability to design such a large plant based on brief user requirement specifications (URS), which were still under development.

To achieve these results, Neste Jacobs delivered:

  • URS review and update
  • Alternative solutions as basis for final selection
  • Process scheduling
  • Comprehensive concept design including plasma cold storage, upstream ethanol fractionation, downstream purification, fill and finish, warehouses, all utilities and supporting functions
  • Project planning and cost estimates
  • Full basic design for the production
Key customer benefits:
  • EMA and China FDA compliant design solutions
  • Full evaluation of URS
  • Robust concept for a greenfield plasma fractionation plant with all supporting functions
  • Plant cost estimate
  • High quality basic design
  • Owner's team support